Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT [letter; comment]

Slavin, S; Naparstek, E; Nagler, A; Kapelushnik, Y; Ackerstein, A; Or, R

doi:10.1182/blood.V87.9.4011.bloodjournal8794011

S Slavin,

S Slavin

Search for other works by this author on:

This Site

PubMed

Google Scholar

E Naparstek,

E Naparstek

Search for other works by this author on:

This Site

PubMed

Google Scholar

A Nagler,

A Nagler

Search for other works by this author on:

This Site

PubMed

Google Scholar

Y Kapelushnik,

Y Kapelushnik

Search for other works by this author on:

This Site

PubMed

Google Scholar

A Ackerstein,

A Ackerstein

Search for other works by this author on:

This Site

PubMed

Google Scholar

R Or

Search for other works by this author on:

This Site

PubMed

Google Scholar

Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT [letter; comment]

Article PDF first page preview

Contents

Data & Figures

Supplemental data

References

Cited By

Email alerts

ASH Publications

American Society of Hematology

Allogeneic cell therapy: the treatment of choice for all hematologic malignancies relapsing post BMT [letter; comment]

Article PDF first page preview

Contents

Data & Figures

Supplemental data

References

Related

Related

Cited By

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only